Semaphorin-3A regulates liver sinusoidal endothelial cell porosity and promotes hepatic steatosis.
Daniel EberhardSydney BalkenholAndrea KösterPaula FollertEric UpschultePhilipp OstermannPhilip KirschnerCelina UhlemeyerIannis CharnayChristina PreussSandra TrenkampBengt-Frederik BelgardtTimo DickscheidIrene EspositoMichael RodenEckhard LammertPublished in: Nature cardiovascular research (2024)
Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, increases worldwide and associates with type 2 diabetes and other cardiometabolic diseases. Here we demonstrate that Sema3a is elevated in liver sinusoidal endothelial cells of animal models for obesity, type 2 diabetes and MASLD. In primary human liver sinusoidal endothelial cells, saturated fatty acids induce expression of SEMA3A, and loss of a single allele is sufficient to reduce hepatic fat content in diet-induced obese mice. We show that semaphorin-3A regulates the number of fenestrae through a signaling cascade that involves neuropilin-1 and phosphorylation of cofilin-1 by LIM domain kinase 1. Finally, inducible vascular deletion of Sema3a in adult diet-induced obese mice reduces hepatic fat content and elevates very low-density lipoprotein secretion. Thus, we identified a molecular pathway linking hyperlipidemia to microvascular defenestration and early development of MASLD.
Keyphrases
- endothelial cells
- fatty acid
- type diabetes
- low density lipoprotein
- adipose tissue
- high glucose
- insulin resistance
- poor prognosis
- high fat diet induced
- protein kinase
- vascular endothelial growth factor
- metabolic syndrome
- high fat diet
- weight loss
- risk factors
- glycemic control
- cardiovascular disease
- tyrosine kinase
- weight gain
- binding protein
- physical activity